Analyst Coverage Initiated: CMPS rating Overweight by Morgan Stanley
Price Target: $30
Report Date: 04-01-2024
Symbol: CMPS - COMPASS Pathways plc
Sector: Healthcare
Industry: Medical Care Facilities
Analyst Coverage Initiated: CMPS rating Overweight by Morgan Stanley
Price Target: $30
COMPASS Pathways plc (CMPS)
1 Ashley Road
Altrincham,
Phone: 44 64 6905 3974
Website: http://www.compasspathways.com
CEO:
NASDAQ, Nasdaq Global Select
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
stock market trading signals, best stock trading signals, best stock trading signals, options trade signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228